(19)
(11) EP 4 100 741 A1

(12)

(43) Date of publication:
14.12.2022 Bulletin 2022/50

(21) Application number: 21750408.3

(22) Date of filing: 04.02.2021
(51) International Patent Classification (IPC): 
G01N 33/564(2006.01)
G01N 33/68(2006.01)
 G01N 33/50(2006.01)
(52) Cooperative Patent Classification (CPC):
G01N 33/564; G01N 33/6854
(86) International application number:
PCT/US2021/016596
(87) International publication number:
WO 2021/158779 (12.08.2021 Gazette 2021/32)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 04.02.2020 US 202062970043 P
06.11.2020 US 202063110476 P

(71) Applicants:
  • Oklahoma Medical Research Foundation
    Oklahoma City, OK 73104 (US)
  • The Board of Regents of the University of Oklahoma
    Norman, OK 73019 (US)

(72) Inventors:
  • FARRIS, A., Darise
    Edmond, OK 73013 (US)
  • LONGOBARDI, Sherri
    Oklahoma City, OK 73159 (US)

(74) Representative: SONN Patentanwälte OG 
Riemergasse 14
1010 Wien
1010 Wien (AT)

   


(54) ANTIBODY TESTS FOR IDENTIFYING RO NEGATIVE SJÖGREN'S SYNDROME AND USE AS BIOMARKERS FOR DYSREGULATED B CELL RESPONSES, B CELL LYMPHOMA, TISSUE FIBROSIS SALIVARY GLAND DYSFUNCTION